Peptides DB
Research-centric peptide and protocol reference hub

Research library

Every indexed study on every peptide in the database, with a machine summary and the numbers that matter pulled out. Filter on the left; the register updates as you go.

2255studies indexed1010with human data129registered trials1946carry a numeric findingLibrarian added 23 studies today
Showing 26 studiesSortNewest indexed
A
grade
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.
Mazdutide (IBI362) · Lancet (London, England) · 2026 · RCT · Phase 3Top journal
Belzutifan plus lenvatinib showed a significant improvement in progression-free survival compared to cabozantinib, but overall survival did not reach statistical significance.
Median progression-free survival 14.8 months (95% CI 11.2-16.6) for belzutifan-lenvatinib vs 10.7 months (95% CI 9.2-11.1) for cabozantinib; HR 0.70, one-sided p<0.0001.
B
grade
Effectiveness of bimekizumab according to previous biologic exposure in patients with plaque psoriasis: a multicenter real-world study.
Mazdutide (IBI362) · The Journal of dermatological treatment · 2026 · Observational · n=98
Biologic-naïve patients achieved faster and deeper responses to bimekizumab compared to those with prior biologic exposure, suggesting it may be beneficial to use this treatment earlier.
PASI reduction was 85.5% vs. 62.5% at week 4, p<0.001.
B
grade
Impact of antithrombotic therapy on outcomes of incidental unruptured intracranial aneurysms in patients with ischemic stroke.
Mazdutide (IBI362) · Annals of medicine · 2026 · Observational · n=197
In patients with small incidental saccular unruptured intracranial aneurysms and acute ischemic stroke, standard antithrombotic regimens do not appear to increase the risk of aneurysm rupture.
Aneurysm rupture occurred in two patients (1.0%) during a mean follow-up of 28.6 ± 18.4 months, n=197.
C
grade
Dual population-level processes contribute to polyclonal ceftiofur heteroresistance in swine-derived &lt;i&gt;Escherichia coli&lt;/i&gt;.
Mazdutide (IBI362) · Virulence · 2026 · Observational
This study highlights the genetic complexity of ceftiofur resistance in swine-derived E. coli, with resistant subpopulations maintaining significant levels even without antibiotic pressure.
Approximately 43% stabilization of resistant subpopulations in EP70A and EP91A under ceftiofur-free conditions.
C
grade
Dual β-lactam therapy against high-risk Pseudomonas aeruginosa isolates: a dynamic in-vitro infection model study integrating population genomics with quantitative systems pharmacology modelling and simulations.
Mazdutide (IBI362) · The Lancet. Microbe · 2026 · Animal studyTop journal
Combination therapy with ceftolozane-tazobactam and meropenem may suppress bacterial resistance more effectively than monotherapy in treating Pseudomonas aeruginosa infections.
Combination therapy resulted in bacterial counts ≥2 log10 CFU per mL lower than the best performing monotherapy.
A
grade
Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Mazdutide (IBI362) · PubMed · 2026 · Meta-analysis · n=1200
Mazdutide showed dose-dependent reductions in body weight and HbA1c in adults with obesity and type 2 diabetes, but the evidence is limited and requires further validation.
MD -11.1% body weight vs placebo at 6 mg, n=2292.
A
grade
Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes.
Mazdutide (IBI362) · europepmc · 2025 · RCT
Exenatide and glucagon co-infusion may increase myocardial glucose uptake and improve certain markers of heart function in adults with type 2 diabetes, but further research is needed to confirm these effects and their clinical significance.
Myocardial glucose uptake increased from a median of 9.2×10^-3 µmol/g/min to 20×10^-3 µmol/g/min, n=8, P<0.05.
Showing 25 of 26